Veterinary drug composition for preventing and treating coccidiosis and preparation method thereof

Abstract

The invention relates to the technical field of veterinary drugs, in particular to a veterinary drug composition for preventing and treating coccidiosis and a preparation method thereof.The veterinary drug composition comprises a microbial preparation and a medicinal material composition, and the mass ratio of the microbial preparation to the medicinal material composition is 0.5: 1-1: 1; the medicinal material composition is prepared from the following components in parts by mass: 15 to 20 parts of herba artemisiae annuae; 25 to 30 parts of antifebrile dichroa; 8 to 12 parts of hairyvein agrimony; 2-4 parts of garden burnet; 5 to 10 parts of honeysuckle flower; 5-10 parts of Chinese pulsatilla root; 3-7 parts of coptis chinensis; 8 to 12 parts of radix astragali seu hedysari; 2-5 parts of ganoderma lucidum spore powder; 1 to 3 parts of glycyrrhizic acid; 2 to 5 parts of prebiotics; 0.5 to 2 parts of curcumin; 0.1 part to 0.5 part of vitamin E; 2-5 parts of betel nut; 2 to 5 parts of cortex meliae; the microbial preparation comprises bacillus licheniformis, bacillus subtillis, clostridium butyricum, lactobacillus plantarum and lactobacillus acidophilus. New components with a synergistic effect are introduced, the preparation process is optimized, and the preparation method is more efficient and safer and has good economic benefits.

Description

Technical Field

[0001] The present invention relates to the technical field of veterinary drugs, and specifically provides a veterinary drug composition for preventing and treating coccidiosis and a preparation method thereof. Background Art

[0002] Coccidiosis is a common and severely harmful parasitic disease caused by coccidia of the genus Eimeria parasitizing in the intestinal epithelial cells or bile ducts of livestock and poultry. This disease is particularly prominent in chicken farming. After infection, symptoms such as listlessness, loss of appetite, weight loss, and diarrhea may occur, and it may also cause the presence of shed intestinal mucosa and blood in the feces. Coccidia have strong resistance and are difficult to completely eliminate under conventional disinfection conditions, bringing huge economic losses to the breeding industry.

[0003] Currently, antibiotics and chemical drugs are mainly used in the market to prevent and treat coccidiosis, such as antibiotics like maduramycin, salinomycin, monensin, etc., and chemical synthetic drugs such as amprolium, clopidol, toltrazuril, and diclazuril. However, these traditional drugs have problems such as large side effects, easy generation of drug resistance, difficulty in controlling the dosage, harm of drug residues, and high prevention and treatment costs. Therefore, the development of a new type of drug for preventing and treating coccidiosis with high efficiency, safety, low residue, and low tendency to generate drug resistance has become an urgent need.

[0004] In recent years, with the increasing attention to natural products, traditional Chinese medicines have gradually received attention due to their characteristics such as small toxic and side effects and low tendency to generate drug resistance. Based on the theory of traditional Chinese veterinary medicine and combined with modern bioengineering technology, rational compatibility of specific traditional Chinese medicines and probiotics can effectively improve the prevention and treatment effect and improve the health status of animals. However, existing traditional Chinese medicine compositions often have problems such as complex prescriptions, high costs, and low absorption and utilization rates, which limit their wide application. Summary of the Invention

[0005] Aiming at the deficiencies of the prior art, the present invention provides a veterinary drug composition for preventing and treating coccidiosis and a preparation method thereof, solving the problems in the above background art.

[0006] According to the first aspect of the present invention, there is provided a veterinary drug composition for preventing and treating coccidiosis, including a microbial preparation and a medicinal material composition, and the mass ratio of the microbial preparation to the medicinal material composition is 0.5:1 - 1:1; The medicinal material composition includes the following in parts by mass: Artemisia annua: 15 parts - 20 parts; Dichroa febrifuga: 25 parts - 30 parts; Agrimonia pilosa: 8 parts - 12 parts; Sanguisorba officinalis: 2 parts - 4 parts; Lonicera japonica: 5 parts - 10 parts; Pulsatilla chinensis: 5 parts - 10 parts; Coptis chinensis Franch.: 3 parts - 7 parts; Astragalus membranaceus (Fisch.) Bunge: 8 parts - 12 parts; Ganoderma lucidum spore powder: 2 parts - 5 parts; Glycyrrhizic acid: 1 part - 3 parts; Prebiotics: 2 parts - 5 parts; Curcumin: 0.5 part - 2 parts; Vitamin E: 0.1 part - 0.5 part; Areca catechu L.: 2 parts - 5 parts; Melia azedarach L. bark: 2 parts - 5 parts; The microbial preparation comprises Bacillus licheniformis, Bacillus subtilis, Clostridium butyricum, Lactobacillus plantarum and Lactobacillus acidophilus.

[0007] According to an embodiment of the present invention, the mass ratio of Bacillus licheniformis, Bacillus subtilis and Clostridium butyricum is 1:1:1; the mass ratio of Lactobacillus plantarum and Lactobacillus acidophilus is 1:1.

[0008] According to a second aspect of the present invention, there is provided a method for preparing the above veterinary drug composition for preventing and treating coccidiosis, Crush the medicinal material composition to nano-level fineness and pass through a 120 - 200 mesh sieve to obtain medicinal material powder; Add a mixed probiotic composed of Bacillus licheniformis, Bacillus subtilis and Clostridium butyricum to the medicinal material powder, set the fermentation temperature at 37°C, and keep the fermentation for 3 days; In the medicinal material powder after the preliminary fermentation, add a mixed probiotic composed of Lactobacillus plantarum and Lactobacillus acidophilus to the fermented medicinal material powder, and continue to ferment at 37°C for an additional 2 days; After the fermentation is completed, purify, concentrate the extract, and process it under freeze-drying conditions to finally obtain a traditional Chinese medicine composition for preventing and treating coccidiosis; In the final product preparation stage, add Ganoderma lucidum spore powder, glycyrrhizic acid, prebiotics, curcumin and vitamin E to obtain the veterinary drug composition.

[0009] According to an embodiment of the present invention, the purification step is carried out by centrifugation, and the centrifugation speed is 6000 - 8000 rpm.

[0010] According to an embodiment of the present invention, the relative density of the concentrated liquid obtained after concentration is controlled at 1.10 - 1.30.

[0011] According to an embodiment of the present invention, the temperature during freeze-drying is set at -30 to -45°C, and the time is set at 6 - 10 hours.

[0012] According to an embodiment of the present invention, after the fermentation is completed, the total bacterial content of the microbial preparation is also 1.0×10^8 CFU / mL.

[0013] According to an embodiment of the present invention, it further includes filtering the extract with a microfiltration membrane with a pore size of 0.22 μm to remove residual solid impurities and obtain a clear and transparent liquid.

[0014] According to an embodiment of the present invention, the fermentation temperature is 37 °C.

[0015] The present invention introduces new traditional Chinese medicine components and optimizes the proportion of existing components to form a unique formula, improving the prevention and treatment effect against coccidiosis.

[0016] By adopting nanotechnology and two-stage fermentation method, the dissolution rate of the active ingredients of the drug and the bioavailability are significantly improved, enhancing the therapeutic effect.

[0017] It not only directly acts against coccidia, but also focuses on improving the overall health level of animals, reducing drug residues and preventing the generation of drug resistance.

[0018] The newly added immunomodulators (such as astragalus membranaceus and ganoderma lucidum spore powder), intestinal repair factors (such as glycyrrhizic acid and prebiotics), anti-inflammatory and antioxidant components (such as curcumin and vitamin E), and components that enhance the anthelmintic effect (such as areca nut and cortex meliae) act together to significantly enhance the comprehensive performance of the product.

[0019] Selecting traditional Chinese medicines with low price and wide sources reduces the production cost; all components are natural substances, reducing the potential risks to human health.

[0020] Through strict post-treatment and quality control, it is ensured that the product has good stability and a long shelf life, facilitating transportation and storage.

[0021] In summary, the present invention provides a traditional Chinese medicine composition for preventing and treating coccidiosis and its preparation method with strong innovation, remarkable curative effect, safety and reliability, and easy to promote and apply, which is expected to replace some existing traditional drugs with high cost and high side effects and contribute to the healthy development of the livestock industry.

[0022] As powerful immunomodulators, astragalus membranaceus and ganoderma lucidum spore powder can activate the body's immune system, improve disease resistance, and thus better resist coccidia infection. Glycyrrhizic acid and prebiotics help protect the intestinal mucosa from damage, promote the repair of damaged tissues, maintain the intestinal microecological balance, and reduce inflammatory reactions. Curcumin and vitamin E provide strong anti-inflammatory and antioxidant protection, reduce intestinal inflammation caused by coccidia, and support the overall health recovery. Areca nut and cortex meliae contain a variety of effective anthelmintic active ingredients, which act synergistically with other medicinal materials to further enhance the killing effect on coccidia and reduce the recurrence rate.

[0023] Through the synergistic effects of the above aspects, the traditional Chinese medicine composition of the present invention can not only quickly relieve the symptoms of coccidiosis in a short period of time, but also maintain the healthy state of animals in the long term, achieving the goal of combining prevention and treatment.

[0024] Of course, it is not necessary for any product implementing the present invention to simultaneously achieve all the above-mentioned advantages. Detailed implementation manners

[0025] In the embodiments of this application, a veterinary drug for treating pullorum disease of chickens and its preparation method are provided through the present invention.

[0026] Example 1: Standard formula Medicinal material composition (parts by mass): Artemisia annua: 18 parts Dichroa febrifuga: 27 parts Agrimony: 10 parts Sanguisorba officinalis: 3 parts Honeysuckle: 7 parts Pulsatilla chinensis: 8 parts Coptis chinensis: 5 parts Astragalus membranaceus: 10 parts Ganoderma lucidum spore powder: 4 parts Glycyrrhizic acid: 2 parts Prebiotics: 3 parts Curcumin: 1.5 parts Vitamin E: 0.3 part Areca nut: 3 parts Melia azedarach bark: 4 parts Microbial agent: The mass ratio of Bacillus licheniformis, Bacillus subtilis, Clostridium butyricum, Lactobacillus plantarum and Lactobacillus acidophilus is 1:1:1 and 1:1.

[0027] Preparation method: Carry out according to the steps in the claims.

[0028] Example 2: Increase the content of Astragalus membranaceus Medicinal material composition (parts by mass): Astragalus membranaceus: 12 parts, and other components remain unchanged.

[0029] Microbial agent: The same as in Example 1.

[0030] Preparation method: The same as in Example 1.

[0031] Example 3: Reduce the content of Artemisia annua Medicinal material composition (parts by mass): Artemisia annua: 15 parts, and other components remain unchanged.

[0032] Microbial agent: The same as in Example 1.

[0033] Preparation method: The same as in Example 1.

[0034] Example 4: Adding More Anti-inflammatory and Antioxidant Ingredients Medicinal Herb Composition (parts by mass): Curcumin: 2 parts, Vitamin E: 0.5 part, and other ingredients remain unchanged.

[0035] Microbial Preparation: The same as in Example 1.

[0036] Preparation Method: The same as in Example 1.

[0037] Example 5: Adjusting the Proportion of Probiotics Medicinal Herb Composition (parts by mass): The same as in Example 1.

[0038] Microbial Preparation: The mass ratio of Bacillus licheniformis, Bacillus subtilis, and Clostridium butyricum is 1:1:1; the mass ratio of Lactobacillus plantarum and Lactobacillus acidophilus is adjusted to 2:1.

[0039] Preparation Method: The same as in Example 1.

[0040] Example 6: Strengthening the Anti-parasitic Effect Medicinal Herb Composition (parts by mass): Areca nut: 5 parts, Cortex meliae: 5 parts, and other ingredients remain unchanged.

[0041] Microbial Preparation: The same as in Example 1.

[0042] Preparation Method: The same as in Example 1.

[0043] Control Example Control Example 1: Only Using Traditional Medicinal Herbs Medicinal Herb Composition (parts by mass): Artemisia annua: 18 parts Dichroa febrifuga: 27 parts Agrimonia pilosa: 10 parts Sanguisorba officinalis: 3 parts Lonicera japonica: 7 parts Pulsatilla chinensis: 8 parts Coptis chinensis: 5 parts It does not contain Astragalus membranaceus, Ganoderma lucidum spores, glycyrrhizic acid, prebiotics, curcumin, vitamin E, areca nut, and Cortex meliae.

[0044] Microbial Preparation: None.

[0045] Preparation Method: Only crush the medicinal herbs and mix them without fermentation treatment.

[0046] Control Example 2: Without Probiotics Medicinal Herb Composition (parts by mass): The same as in Example 1.

[0047] Microbial Preparation: None.

[0048] Preparation method: The remaining steps are the same as those in Example 1, except that probiotics are not added.

[0049] Comparative Example 3: Reduction of auxiliary components Medicinal material composition (parts by mass): Does not contain Ganoderma lucidum spore powder, glycyrrhizic acid, prebiotics, curcumin, vitamin E.

[0050] Microbial preparation: The same as in Example 1.

[0051] Preparation method: The same as in Example 1.

[0052] Comparative Example 4: Single medicinal material composition Medicinal material composition (parts by mass): Only contains Artemisia annua, Dichroa febrifuga, Agrimonia pilosa, Sanguisorba officinalis, Lonicera japonica, Pulsatilla chinensis, and Coptis chinensis.

[0053] Microbial preparation: The same as in Example 1.

[0054] Preparation method: The same as in Example 1.

[0055] Experimental example The veterinary drugs of Examples 1-4 and Comparative Examples 1-4 were tested. In order to more comprehensively evaluate the effect of the veterinary drug composition for preventing and treating coccidiosis of the present invention, we added more experimental data, including but not limited to key indicators such as survival rate, relative weight gain rate, anticoccidial index (ACI), blood stool score, and cecal lesion score. The method is as follows: Healthy broiler chickens were used as experimental subjects and divided into several groups with 20 chickens in each group. All chickens were infected with Eimeria tenella by oral infection, and each chicken was inoculated with 6.0×10^4 sporulated oocysts. Then different formulated drugs were given continuously for 7 days. The following indicators were observed and recorded: body weight gain, oocyst excretion in feces, intestinal health status (including intestinal mucosa integrity, etc.), survival rate, relative weight gain rate, anticoccidial index (ACI), blood stool score, and cecal lesion score. The results are shown in Table 1.

[0056] Table 1. Test detection of veterinary drugs of Examples 1-6 and Comparative Examples 1-4

[0057] Survival rate: Refers to the percentage of chickens that survived during the experiment.

[0058] Relative weight gain rate: The calculation formula is (average weight gain of the drug-administered and coccidia-infected experimental group / average weight gain of the blank control group) × 100%, which reflects the effect of the drug on animal growth.

[0059] Anti-Coccidial Index (ACI): It comprehensively considers factors such as relative weight gain rate, survival rate, lesion value, and oocyst value, and is an important indicator for evaluating the efficacy of anti-coccidial drugs. ACI > 180 indicates excellent efficacy.

[0060] Blood stool score: Scored according to the proportion of blood in the feces, 0 indicates no blood in the stool, and 4 indicates severe blood in the stool.

[0061] Cecal lesion score: Based on the lesion scoring method designed by Johnson and Reid, it evaluates the degree of cecal internal lesions, ranging from 0 to 4 points, where 4 points represent the most severe lesions.

[0062] Conclusion It can be seen from the expanded experimental data that the veterinary drug composition provided by the present invention not only shows significant advantages in promoting animal growth, reducing oocyst excretion, and improving intestinal health, but also has obvious effects in increasing survival rate, relative weight gain rate, and anti-coccidial index. In particular, Examples 2, 4, and 6 are superior to other groups in multiple key indicators, showing stronger synergistic effects. In contrast, the comparative examples have significantly worse effects than the examples due to the lack of some important components or the failure to adopt advanced preparation processes. This further proves the uniqueness and superiority of the present invention, especially its high efficiency and safety in practical applications.

[0063] Although the preferred embodiments of the present invention have been described, those skilled in the art can make additional changes and modifications to these embodiments once they know the basic creative concept. Therefore, the appended claims are intended to be construed as including the preferred embodiments and all changes and modifications falling within the scope of the present invention.

[0064] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalent technologies, the present invention is also intended to include these modifications and variations.

Claims

1. A veterinary drug composition for preventing and treating coccidiosis, characterized in that: The invention comprises a microbial preparation and a medicinal material composition, wherein the mass ratio of the microbial preparation to the medicinal material composition is 0.5:1-1:1; the medicinal material composition comprises, in parts by mass: Artemisia annua: 15-20 parts; Changshan: 25-30 portions; Agrimony: 8-12 portions; Sanguisorba officinalis: 2-4 parts; Honeysuckle: 5-10 parts; Pulsatilla: 5-10 portions; Coptis chinensis: 3-7 parts; Astragalus: 8-12 parts; Ganoderma lucidum spore powder: 2-5 parts; Glycyrrhizic acid: 1-3 parts; Prebiotics: 2-5 servings; Curcumin: 0.5-2 parts; Vitamin E: 0.1-0.5 parts; Betel nut: 2-5 portions; Neem bark: 2-5 parts; The microbial preparation comprises Bacillus licheniformis, Bacillus subtilis, Clostridium butyricum, Lactobacillus plantarum and Lactobacillus acidophilus.

2. The veterinary drug composition for preventing and treating coccidiosis according to claim 1, characterized in that: The mass ratio of the Bacillus licheniformis, the Bacillus subtilis and the Clostridium butyricum is 1:1:1; the mass ratio of the Lactobacillus plantarum and the Lactobacillus acidophilus is 1:

1.

3. A method for preparing a veterinary drug composition for preventing and treating coccidiosis according to claim 1 or 2, characterized in that: The medicinal material composition is crushed to nanometer-level fineness and passed through a 120-200 mesh sieve to obtain medicinal material powder; A mixed probiotic consisting of Bacillus licheniformis, Bacillus subtilis and Clostridium butyricum was added to the medicinal powder, the fermentation temperature was set at 37°C, and the fermentation time lasted for 3 days; After the initial fermentation, a mixed probiotic consisting of Lactobacillus plantarum and Lactobacillus acidophilus was added to the fermented medicinal powder, and the fermentation was continued at 37° C. for an additional 2 days; After the fermentation is completed, the extract is purified, concentrated, and processed under freeze-drying conditions to finally obtain a Chinese medicine composition for preventing and treating coccidiosis; In the final product preparation stage, ganoderma lucidum spore powder, glycyrrhizic acid, prebiotics, curcumin and vitamin E are added to obtain the veterinary drug composition.

4. The preparation method according to claim 3, characterized in that: The purification step is carried out by centrifugation at a speed of 6000 to 8000 rpm.

5. The preparation method according to claim 3, characterized in that: The relative density of the concentrated solution obtained after concentration is controlled at 1.10-1.

30.

6. The preparation method according to claim 3, characterized in that: The temperature during freeze drying is set at -30 to -45°C, and the time is set at 6 to 10 hours.

7. The preparation method according to claim 3, characterized in that: After fermentation, the total bacterial content of the microbial preparation was also 1.0×10^8 CFU / mL.

8. The preparation method according to claim 5, characterized in that: The method also includes filtering the extract using a microfiltration membrane with a pore size of 0.22 μm to remove residual solid impurities and obtain a clear and transparent liquid.

9. The preparation method according to claim 5, characterized in that: The fermentation temperature was 37°C.

Images